- Home
- PETS vs IGMS Comparison
PETS vs IGMS Comparison
Compare PETS & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- IGMS
- Stock Information
- Founded
- PETS 1996
- IGMS 1993
- Country
- PETS United States
- IGMS United States
- Employees
- PETS N/A
- IGMS N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- IGMS Health Care
- Exchange
- PETS Nasdaq
- IGMS Nasdaq
- Market Cap
- PETS 70.4M
- IGMS 81.9M
- IPO Year
- PETS N/A
- IGMS 2019
- Fundamental
- Price
- PETS $3.24
- IGMS $1.31
- Analyst Decision
- PETS Sell
- IGMS Hold
- Analyst Count
- PETS 2
- IGMS 8
- Target Price
- PETS $3.35
- IGMS $6.00
- AVG Volume (30 Days)
- PETS 177.2K
- IGMS 569.9K
- Earning Date
- PETS 08-12-2025
- IGMS 08-13-2025
- Dividend Yield
- PETS N/A
- IGMS N/A
- EPS Growth
- PETS N/A
- IGMS N/A
- EPS
- PETS 0.02
- IGMS N/A
- Revenue
- PETS $247,010,000.00
- IGMS $145,050,000.00
- Revenue This Year
- PETS N/A
- IGMS $252.44
- Revenue Next Year
- PETS N/A
- IGMS $46.48
- P/E Ratio
- PETS $189.87
- IGMS N/A
- Revenue Growth
- PETS N/A
- IGMS 4882.82
- 52 Week Low
- PETS $2.90
- IGMS $0.92
- 52 Week High
- PETS $6.85
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- PETS 44.94
- IGMS 56.53
- Support Level
- PETS $3.00
- IGMS $1.25
- Resistance Level
- PETS $4.10
- IGMS $1.29
- Average True Range (ATR)
- PETS 0.22
- IGMS 0.03
- MACD
- PETS -0.02
- IGMS -0.00
- Stochastic Oscillator
- PETS 21.82
- IGMS 52.17
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.